UroToday.com - Endocrine treatment (ET), which interrupts testosterone regulation of the prostate tumor, is the cornerstone treatment for men with locally advanced or metastatic prostate cancer. A number of metabolic side-effects have been reported including increased body weight, insulin...
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two...